Description

AstraZeneca: The $6 Billion Imfinzi Story Is Expanding Beyond Lung Cancer

AstraZeneca has steadily built one of the most diversified oncology portfolios in the pharmaceutical industry, and a single drug increasingly sits at the center of that strategy: Imfinzi. Originally launched in 2017 as an immunotherapy for lung cancer, the drug has gradually expanded into multiple tumor types, including bladder, liver, biliary tract, and endometrial cancers. The latest milestone came with regulatory approval in Europe allowing Imfinzi to be used in combination with chemotherapy for early-stage gastric and gastroesophageal cancers, marking yet another step in the drug’s expanding clinical footprint. The approval reflects a broader trend within oncology where immunotherapies are increasingly being deployed across different cancer types and earlier stages of disease. Imfinzi has already become one of AstraZeneca’s most commercially important medicines, generating more than $6 billion in annual sales and ranking as the company’s second-largest oncology product behind Tagrisso.